Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by “insufficient resources” at the FDA. The new data has been extended from 25th November to 24th February next…
Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by “insufficient resources” at the FDA. The new data has been extended from 25th November to 24th February next…
